# US 2012/0251522 A2 · Targeted delivery of therapeutic agents with lyophilized matrices

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251522 A2
- Document ID: US20120251522A2
- Status: Published application
- Kind: A2
- Application number: 12/513,161
- Filed: 2007-10-31
- Published: 2012-10-04
- Earliest claimed: 2006-10-31
- Assignees: University of Rochester
- Inventors: Hani Awad; Edward Schwarz
- Web page: https://patentgrep.com/patent/US20120251522A2

## CPC

- A61L 27/3604: {characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel}
- A61K 35/32: Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
- A61K 38/1875: {Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61L 27/24: Collagen
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- C12N 15/86: Viral vectors
- A61L 2300/256: Antibodies, e.g. immunoglobulins, vaccines
- A61L 2300/258: Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
- A61L 2300/412: Tissue-regenerating or healing or proliferative agents
- A61L 2430/10: for reconstruction of tendons or ligaments
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Embodiments of surgical grafts, and methods, for the delivery of therapeutic agents to a target tissue via acellular matrices, are described. In some embodiments, nonviable matrices are successful in preventing or lessening adhesion formation by guiding tissue repair and remodeling, while also providing the target tissue with therapeutic agents that can act as repair and remodeling factors. An exemplary method to modulate flexor tendon healing and provide elimination or reduction of fibrotic adhesions involves loading a freeze-dried flexor digitorum longus allograft with recombinant adeno-associated viral (rAAV) vectors for the targeted and transient expression of growth/differentiation factor 5 (GDF5).

## Claims

### Claim 1

A surgical graft, for use in promoting healing of a diseased or injured tissue, comprising:
a nonviable, substantially acellular, lyophilized, biologically derived matrix; and
at least one therapeutic agent, releasably coupled to the matrix;
wherein the graft is sized and shaped to be placed in a patient's body in proximity to a diseased or injured tissue;
wherein, when the graft is placed in the body, the at least one therapeutic agent is released into the tissue; and
wherein the at least one therapeutic agent is effective to promote healing of the tissue.

### Claim 2 (depends on 1)

The graft of claim 1, wherein the healing comprises at least one of tissue remodeling, accelerating wound healing, achieving a reduced adhesion coefficient, and enhancing cell repopulation.

### Claim 3 (depends on 1)

The graft of claim 1, wherein the healing comprises at least one of improving joint flexion, improving joint range of motion, and improving tendon gliding.

### Claim 4 (depends on 1)

The graft of claim 1, wherein the matrix comprises a collagen.

### Claim 5 (depends on 4)

The graft of claim 4, wherein the collagen is derived from at least one of tendon and ligament.

### Claim 6 (depends on 1)

The graft of claim 1, wherein the at least one therapeutic agent is adsorbed to the matrix.

### Claim 7 (depends on 1)

The graft of claim 1, wherein release of the at least one therapeutic agent is a sustained release.

### Claim 8 (depends on 1)

The graft of claim 1, wherein the at least one therapeutic agent comprises:
an expression system, configured to result in expression of at least one therapeutic protein;
wherein the expression system comprises at least one of a virus, a plasmid, a bacteriophage, a chromosome, a yeast artificial chromosome, a cosmid, and a linear DNA fragment.

### Claim 9 (depends on 1)

The graft of claim 1, wherein the therapeutic agent comprises a recombinant adeno-associated virus.

### Claim 10 (depends on 8)

The graft of claim 8, wherein the expression system comprises a nucleic acid comprising at least about 80% sequence identity to (a) a nucleic acid from about position 500 to about position 2020 of SEQ ID NO: 1, or (b) the complement of the nucleotide sequence of (a).

### Claim 11 (depends on 8)

The graft of claim 8, wherein the expression system comprises a nucleic acid encoding a protein having at least about 80% sequence identity to a protein defined by SEQ ID NO: 2.

### Claim 12 (depends on 1)

The graft of claim 1, wherein the at least one therapeutic agent comprises a GDF5 receptor agonist.

### Claim 13 (depends on 12)

The graft of claim 12, wherein the GDF5 receptor agonist comprises a protein having substantial homology to a protein as defined by SEQ ID NO: 2.

### Claim 14 (depends on 12)

The graft of claim 12, wherein the GDF5 receptor agonist comprises an antibody configured to bind and activate a GDF5 receptor.

### Claim 15 (depends on 1)

The graft of claim 1, wherein the at least one therapeutic agent comprises a protein having at least about 80% sequence identity to a protein as defined by SEQ ID NO: 2.

### Claim 16

A method, of promoting healing of a diseased or injured tissue, comprising:
providing a graft, comprising:
a nonviable, substantially acellular, lyophilized, biologically derived matrix; and
at least one therapeutic agent, releasably coupled to the matrix;
wherein the graft is sized and shaped to be placed in a patient's body in proximity to a diseased or injured tissue;
wherein the at least one therapeutic agent is effective to promote healing of the tissue; and
placing the graft in the body, such that the at least one therapeutic agent is released into the tissue.

### Claim 17 (depends on 16)

The method of claim 16, wherein the healing comprises at least one of tissue remodeling, accelerating wound healing, achieving a reduced adhesion coefficient, and enhancing cell repopulation.

### Claim 18 (depends on 16)

The method of claim 16, wherein the healing comprises at least one of improving joint flexion, improving joint range of motion, and improving tendon gliding.

### Claim 19 (depends on 16)

The method of claim 16, wherein the matrix comprises a collagen.

### Claim 20 (depends on 16)

The method of claim 16, wherein the at least one therapeutic agent comprises:
an expression system, configured to result in expression of at least one therapeutic protein;
wherein the expression system comprises at least one of a virus, a plasmid, a bacteriophage, a chromosome, a yeast artificial chromosome, a cosmid, and a linear DNA fragment.

### Claim 21 (depends on 16)

The method of claim 16, wherein the therapeutic agent comprises a recombinant adeno-associated virus.

### Claim 22 (depends on 16)

The method of claim 16, wherein the expression system comprises a nucleic acid comprising at least about 80% sequence identity to (a) a nucleic acid from about position 500 to about position 2020 of SEQ ID NO: 1, or (b) the complement of the nucleotide sequence of (a).

### Claim 23 (depends on 16)

The method of claim 16, wherein the at least one therapeutic agent comprises a GDF5 receptor agonist.

### Claim 24 (depends on 16)

The method of claim 16, wherein the at least one therapeutic agent comprises a protein having at least about 80% sequence identity to a protein as defined by SEQ ID NO: 2.

### Claim 25 (depends on 16)

The method of claim 16, wherein the diseased or injured tissue comprises at least one of a rotator cuff, an Achilles tendon, a flexor tendon, an extensor tendon, a ligament, a bone, and cartilage.
